SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Quest PharmaTech Inc. Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.